IBC Speakers Predict Reimbursement Woes For Personalized Diagnostic Tests
This article was originally published in The Gray Sheet
Executive Summary
Variation in local Medicare coverage policies for Genentech's Herceptin demonstrates the difficulty CMS will face as predictive molecular diagnostic test use becomes more prevalent, according to Covance VP-Health Economics and Outcome Services David Parker
You may also be interested in...
FDA Pharmacogenetic Regulation: Three Guidances, Fall Workshop
FDA is planning to issue three guidances on pharmaco-genomics over the next 18 months
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.